Dmitry Balyasny’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.25M | Sell |
2,307
-34,316
| -94% | -$19.3M | ﹤0.01% | 2090 |
|
|
2026
Q1 | $21.7M | Sell |
36,623
-19,311
| -35% | -$9.62M | 0.03% | 656 |
|
|
2025
Q4 | $27.3M | Sell |
55,934
-90,964
| -62% | -$42.4M | 0.03% | 578 |
|
|
2025
Q3 | $61.6M | Sell |
146,898
-5,829
| -4% | -$1.96M | 0.08% | 296 |
|
|
2025
Q2 | $43.9M | Buy |
152,727
+136,883
| +864% | +$40.9M | 0.07% | 377 |
|
|
2025
Q1 | $4.88M | Buy |
+15,844
| New | +$5.43M | 0.01% | 1255 |
|
|
2024
Q1 | – | Sell |
-66,460
| Closed | -$14.6M | – | 3149 |
|
|
2023
Q4 | $14.6M | Sell |
66,460
-14,078
| -17% | -$3.24M | 0.03% | 722 |
|
|
2023
Q3 | $18.2M | Buy |
80,538
+39,968
| +99% | +$9.21M | 0.04% | 607 |
|
|
2023
Q2 | $8.96M | Sell |
40,570
-18,987
| -32% | -$4.21M | 0.02% | 837 |
|
|
2023
Q1 | $13.3M | Buy |
59,557
+14,819
| +33% | +$3.65M | 0.03% | 670 |
|
|
2022
Q4 | $12.4M | Sell |
44,738
-115,039
| -72% | -$29M | 0.03% | 647 |
|
|
2022
Q3 | $33.5M | Buy |
159,777
+55,173
| +53% | +$12.3M | 0.1% | 257 |
|
|
2022
Q2 | $24.6M | Buy |
+104,604
| New | +$21.3M | 0.08% | 359 |
|
|
2021
Q4 | – | Sell |
-9,918
| Closed | -$1.83M | – | 2619 |
|
|
2021
Q3 | $1.83M | Buy |
+9,918
| New | +$1.95M | 0.01% | 1169 |
|
|
2021
Q2 | – | Sell |
-12,263
| Closed | -$2.05M | – | 2371 |
|
|
2021
Q1 | $2.05M | Buy |
12,263
+3,591
| +41% | +$599K | 0.01% | 1008 |
|
|
2020
Q4 | $1.32M | Buy |
+8,672
| New | +$1.14M | 0.01% | 963 |
|
|
2019
Q4 | – | Sell |
-8,432
| Closed | -$672K | – | 1506 |
|
|
2019
Q3 | $672K | Sell |
8,432
-3,264
| -28% | -$263K | ﹤0.01% | 899 |
|
|
2019
Q2 | $913K | Buy |
+11,696
| New | +$1.09M | 0.01% | 1103 |
|
|
2018
Q3 | – | Sell |
-4,860
| Closed | -$550K | – | 2056 |
|
|
2018
Q2 | $550K | Buy |
4,860
+453
| +10% | +$49.8K | ﹤0.01% | 1322 |
|
|
2018
Q1 | $495K | Buy |
+4,407
| New | +$560K | ﹤0.01% | 1451 |
|
|
2017
Q4 | – | Sell |
-3,200
| Closed | -$375K | – | 2338 |
|
|
2017
Q3 | $375K | Buy |
+3,200
| New | +$409K | ﹤0.01% | 1442 |
|
|
2017
Q2 | – | Sell |
-7,620
| Closed | -$1.03M | – | 1763 |
|
|
2017
Q1 | $1.03M | Buy |
+7,620
| New | +$1.15M | ﹤0.01% | 1089 |
|
|
2016
Q1 | – | Sell |
-1,763
| Closed | -$276K | – | 1543 |
|
|
2015
Q4 | $276K | Buy |
+1,763
| New | +$257K | ﹤0.01% | 997 |
|
Other funds holding UTHR
ACA
JT
Dmitry Balyasny's UTHR Position: Q2 2026 in Review
Dmitry Balyasny reduced its United Therapeutics (UTHR) stake by 94% in Q2 2026, selling an estimated $19.3M and leaving 2,307 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2090.
Dmitry Balyasny first reported a position in UTHR in Q4 2015 and has held it in 23 quarters since. The position peaked at $61.6M in Q3 2025. 874 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- Dmitry Balyasny held 2,307 shares of United Therapeutics worth $1.25M as of Q2 2026.
- Dmitry Balyasny sold 34,316 United Therapeutics shares in Q2 2026, an estimated $19.3M.
- United Therapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2090 holding.
- Dmitry Balyasny first reported a position in United Therapeutics in Q4 2015 and has held it in 23 quarters since.
- Dmitry Balyasny's United Therapeutics position peaked at $61.6M in Q3 2025.
- 874 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.